UCB SA (OTCMKTS:UCBJY – Get Free Report) crossed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $97.61 and traded as high as $98.95. UCB shares last traded at $98.79, with a volume of 9,578 shares traded.
UCB Trading Down 0.2 %
The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33. The company’s 50-day moving average is $97.49 and its 200-day moving average is $95.61.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Recommended Stories
- Five stocks we like better than UCB
- Low PE Growth Stocks: Unlocking Investment Opportunities
- FedEx Delivers Another Crushing Blow to Its Stock Price
- High Flyers: 3 Natural Gas Stocks for March 2022
- Analysts Stay Bullish on Rocket Lab as Signs of a Bottom Emerge
- Most active stocks: Dollar volume vs share volume
- Micron Stock Will Retest All-Time Highs This Year
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
